TABLE 5

Surgical and medical management of patients with invasive fungus-infected case woundsa

CharacteristicbPresence of fungusP value
MucoralesNon-MucoralesTotal
Total no. of patientsc192645
OR visits at LRMC and U.S. MTFs (median [IQR])d10.5 (9.0–14.0)9.0 (6.0–11.0)9.0 (6.0–12.0)0.003
Type of antifungal usagee∼1.0
    Single2 (10.5)2 (7.7)4 (8.9)
    Double13 (68.4)19 (73.1)32 (71.1)
    Triple4 (21.1)5 (19.2)9 (20)
Timing of receipt of first antifungal following injury
    Median days (IQR)8.0 (6.0–10.0)9.5 (7.0–12.0)9.0 (6.0–11.0)0.25
    Received antifungals within (no. [IQR]):0.43
        ≤7 days8 (42.1)8 (30.8)16 (35.6)
        >7 days11 (57.9)18 (69.2)29 (64.4)
Duration of antifungal use
    Days (median [IQR])31.0 (22.0–44.0)28.5 (19.0–47.0)31.0 (20.0–45.0)0.88
    Receipt of antifungals (no. [%]):0.20
        ≤21 days4 (21.1)11 (42.3)15 (33.3)
        >21 days15 (78.9)15 (57.7)30 (66.7)
  • a Data are on a per patient basis.

  • b IQR, interquartile range; LRMC, Landstuhl Regional Medical Center; MTF, military treatment facility; OR, operating room.

  • c Extreme observations and outliers were excluded from the antifungal analysis. Overall patient totals are 5 for single, 32 for double, and 12 for triple.

  • d OR visit data are on a per wound basis from the population of 45 patients (29 wounds with Mucorales and 48 wounds without Mucorales).

  • e Single, amphotericin B or voriconazole; double, amphotericin B plus a triazole; triple, amphotericin B, a triazole, and an echinocandin.